articleTop 1% cited

RESULTS FROM A HUMAN RENAL ALLOGRAFT TOLERANCE TRIAL EVALUATING THE HUMANIZED CD52-SPECIFIC MONOCLONAL ANTIBODY ALEMTUZUMAB (CAMPATH-1H)

Transplantation · 2003 · Vol. 76(1) · pp. 120–129

Allan D. Kirk✉Douglas A. HaleRoslyn B. MannonDavid E. Kleiner(National Cancer Institute)Steven C. HoffmannRobert L. KampenLinda K. CendalesDouglas K. TadakiDavid M. HarlanS. John Swanson(Walter Reed Army Institute of Research)

View via DOI Publisher page

Abstract

T-cell depletion alone does not induce tolerance in humans. These data underscore a prominent role for early responding monocytes in human allograft rejection.

Renal Transplantation Outcomes and Treatments T-cell and B-cell Immunology Cytomegalovirus and herpesvirus researchAlemtuzumabCD52ImmunosuppressionMedicineImmunologyTransplantationAllotransplantationSirolimusImmune toleranceT cell

MeSH terms

AlemtuzumabAdultAntibodies, MonoclonalAntibodies, NeoplasmBlack or African AmericanFemaleFollow-Up StudiesGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsLymph NodesLymphocyte DepletionMaleMiddle Aged

Citations

436

FWCI

16.48

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Immunocompetent T-Cells with a Memory-Like Phenotype are the Dominant Cell Type Following Antibody-Mediated T-Cell Depletion